BACKGROUND: Two treatments, ranibizumab and @entity619 implant, for @entity227 due to @entity4 ( @entity4 ) secondary to @entity2994 ( @entity2994 ) have recently been studied in clinical trials. There have been no head to head comparisons of the two treatments, and improvement measured as gain in Best Corrected Visual Acuity (BCVA) was reported using different outcomes thresholds between trials. To overcome these limitations, and inform an economic model, we developed a combination of a multinomial model and an indirect Bayesian comparison model for multinomial outcomes. METHODS: Outcomes of change from baseline in BCVA for @entity619 compatible with those available for ranibizumab, reported by 4 randomised controlled trials, were estimated by fitting a multinomial distribution model to the probability of a @entity1 achieving outcomes in a range of changes from baseline in BCVA (numbers of letters) at month 1. A Bayesian indirect comparison multinomial model was then developed to compare treatments in the Branch @entity2994 (BRVO) and Central @entity2994 (CRVO) populations. RESULTS: The multinomial model had excellent fit to the observed results. With the Bayesian indirect comparison, the probabilities of achieving >= 20 letters, with 95% credible intervals, at month 1 in @entity1 with BRVO were 0.191 (0.130, 0.261) with ranibizumab and 0.093 (0.027, 0.213) with @entity619 . In @entity1 with CRVO, probabilities were 0.133 (0.082, 0.195) (ranibizumab) and 0.063 (0.016, 0.153) ( @entity619 ). Probabilities of a gain in >= 10 letters in BRVO @entity1 were 0.500 (0.365, 0.650) v 0.459 (0.248, 0.724) and in CRVO @entity1 0.459 (0.332, 0.602) v 0.498 (0.263, 0.791) for ranibizumab and @entity619 treatments respectively. The comparisons also favoured ranibizumab at month 6 although changes to therapies after month 3 may have introduced bias. CONCLUSION: The newly developed combination of multinomial and indirect Bayesian comparison models indicated a trend for ranibizumab association with a greater percentage of @entity4 @entity1 achieving @entity227 than @entity619 at months 1 and 6 in a common clinical context, although results were not classically significant. The method was a useful tool for comparisons of probability distributions between clinical trials that reported events on different categorical scales and estimates can be used to inform economic models.

Indirect comparisons of ranibizumab and @entity619 in @entity4 secondary to XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity227 :: ('MESH:D014786', 'Disease') :: ['visual gains', 'visual impairment'] @entity2994 :: ('MESH:D012170', 'Disease') :: ['retinal vein occlusion', 'RVO'] @entity4 :: ('MESH:D004487', 'Disease') :: ['ME', 'macular oedema'] @entity619 :: ('MESH:D003907', 'Chemical') :: ['dexamethasone']
@entity2994 :: (MESH:D012170,Disease) :: ['retinal vein occlusion']
